key: cord-0943275-xg77xy3v
authors: Guyton, John R.
title: From the editor: Confronting a pandemic or two
date: 2020-04-30
journal: Journal of Clinical Lipidology
DOI: 10.1016/j.jacl.2020.03.003
sha: c5caa3f2e44d91726574c359172533485dcecfa1
doc_id: 943275
cord_uid: xg77xy3v

nan

From the editor: Confronting a pandemic or two

The COVID-19 viral pandemic is bearing down on the United States. Thousands have died in China and in Italy, and every country in the world is or will be affected. At home every sniffle or cough elicits a brief pang of fear. To fight the deadly virus, we are turning to methods that proved partly effective in the flu epidemic of 1918. We have learned a new term-social distancing.

Oddly at a time when the interdependence of humans all over the world is most exposed, we are asked to isolate ourselves. To do the best for the most vulnerable among us, the right response is to shut the doors and hunker down. It's just the opposite of the best medical intentions to reach out, to touch, and to help. Yet the time will come, and for some the time is now, when those intentions rise again to action. Perhaps we can take a lesson from these days of isolation to remember how human flourishing depends on social life.

There is another pandemic called atherosclerosis that claims millions of lives annually worldwide. It's so familiar that we are apt to forget it in these extraordinary days. Yet we can point to signs of success. I have 2 brothers whose livelihood has depended partly on performing coronary bypass surgery. I recall my surprise early in my medical career when this complex operation became the most commonly performed surgery in the US. By 2000 one brother told me that the pace of performing coronary bypass procedures was declining about 1% per year. That pace has accelerated. Since 2003 the annual number of bypass procedures has dropped by 50%. The annual number of percutaneous coronary interventions (PCI) by cardiologists is a little more than twice the rate of bypass procedures. PCI volume has likewise dropped by half since 2003. 1 So we find ourselves facing an old type of communicable disease today, yet gaining substantial success in battling the most prevalent modern deadly pathology in both developed and emerging economies in the world. In particular, medical, dietary, and lifestyle interventions are working to diminish the impact of atherosclerosis, signaled by far less need for invasive procedures. Preventive cardiology and lipidology are rising. Joint efforts and international cooperation make the mission particularly satisfying.

In this issue of JCL we focus in 2 editorials and the Roundtable on atherosclerotic risk in South Asians, defined as the nations of India, Pakistan, Nepal, Bhutan, Bangladesh, Sri Lanka, and Maldives as well as the worldwide diaspora emanating therefrom. South Asians comprise 25% of world population, but suffer 50% of atherosclerotic cardiovascular events. Dr Raman Puri and colleagues have founded the India Lipid Association, and this issue marks the publication in JCL of their online-only, open access expert consensus document applicable to LDL cholesterol goals in India. They discuss potential expanded use of PCSK9 inhibitors to meet LDL cholesterol goals as low as #30 mg/dL. 2 You will also find in these pages a discussion of the sphingolipid ceramide as an atherosclerotic risk factor, illustrative cases including a woman with intermittent autoimmune chylomicronemia, advice on how to differentiate familial from multifactorial chylomicronemia, a suggestion that ABCG5/G8 heterozygous pathogenic variants may contribute to familial hypercholesterolemia, ascertainment of hurdles facing cascade screening and pediatric cholesterol screening, and several other new aspects of clinical lipidology.

Trends in Characteristics and Outcomes of Patients Undergoing Coronary Revascularization in the United States

Proposed low density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert Consensus Statement from Lipid Association of India

Dr Guyton has received research grants from Amarin, Regeneron, and Sanofi. John R. Guyton, MD Professor of Medicine Duke University Medical Center Durham, NC, USA E-mail address: john.guyton@duke.edu